Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-‘749) and its long-term systemic safety profile was consistent with…Read More
You might also be interested in reading Wall Street Pulls Back After Rally as AI Trade Faces Reality Check.